Hematopoietic Agents - Hematopoietic Gene Therapy Agents

Hematopoietic agents in the gene therapy category comprise autologous, cell-based gene therapies derived from patient hematopoietic stem and progenitor cells that undergo ex vivo genetic modification Once engrafted in the bone marrow, they provide a durable source of functional blood and immune cells, offering potentially curative treatment for severe monogenic hematologic and neurometabolic disorders, including sickle cell disease, transfusion-dependent beta-thalassemia, severe combined immunod...

Hematopoietic agents in the gene therapy category comprise autologous, cell-based gene therapies derived from patient hematopoietic stem and progenitor cells that undergo ex vivo genetic modification

Utilizing delivery platforms such as viral vectors or targeted gene-editing technologies, these agents insert functional therapeutic genes or edit endogenous DNA to correct underlying molecular defects before the modified cells are reinfused following myeloablative conditioning

Utilizing delivery platforms such as viral vectors or targeted gene-editing technologies, these agents insert functional therapeutic genes or edit endogenous DNA to correct underlying molecular defects before the modified cells are reinfused following myeloablative conditioning Once engrafted in the bone marrow, they provide a durable source of functional blood and immune cells, offering potentially curative treatment for severe monogenic hematologic and neurometabolic disorders, including sickl...

Once engrafted in the bone marrow, they provide a durable source of functional blood and immune cells, offering potentially curative treatment for severe monogenic hematologic and neurometabolic disorders, including sickle cell disease, transfusion-dependent beta-thalassemia, severe combined immunodeficiency, and cerebral adrenoleukodystrophy